Abbott Laboratories vs Illinois Tool Works Inc. — how do they compare? Abbott Laboratories trades at $110.22 (market cap $187.95B), while Illinois Tool Works Inc. trades at $292.68 (market cap $83.49B). The key difference: Abbott Laboratories is far larger — about 2.3× Illinois Tool Works Inc.'s market cap, and Illinois Tool Works Inc. pays the higher dividend (2.35%). Which is the better fit depends on your goals.
| ABT | ITW | |
|---|---|---|
Market Cap | $187.95B | $83.49B |
Sector | Health | Industrials |
52-Week High | $136.62 | $299.60 |
52-Week Low | $82.57 | $241.07 |
Enterprise Value | $214.96B | $92.34B |
Dividend Yield | 2.32% | 2.35% |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
ITW trades at $294.52, down 0.72% today, with bullish technical signals from moving averages and a consensus price target of $314.25 representing 6.7% upside. The company has beaten earnings estimates for three consecutive quarters, maintains strong profitability with 19.39% net margins, and recently announced a 7% dividend increase alongside a $6 billion share repurchase program. Revenue remains stable around $16 billion annually with consistent cash flow generation.
The outlook remains positive given strong operational execution and shareholder returns, though valuation multiples appear elevated with a P/E of 26.55. Key risks include potential margin pressure from economic cycles and high debt levels at 55.54% of assets. The stock offers quality exposure to industrial recovery with disciplined capital allocation.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →